HANALL BIOPHARMA
LIVE

Serial Number

79389998

Owner

Hanall Biopharma Co., Ltd.

Attorney

John M. Kim

Filing Date

Dec 7, 2023

Add to watchlist:

No watchlists yet
View on USPTO

HANALL BIOPHARMA Trademark

Serial Number: 79389998 • Registration: 7617145

HANALL BIOPHARMA is a trademark filed by Hanall Biopharma Co., Ltd. on December 7, 2023. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 35 (Advertising & Business). The application is currently registered and active.

Owner Contact Info

Hanall Biopharma Co., Ltd. (3 trademarks)

43, Sangseodang 1-gil, Daedeok-gu

Entity Type: 03

Trademark Details

Filing Date

December 7, 2023

Registration Date

December 24, 2024

Published for Opposition

October 22, 2024

Goods & Services

Price comparison services; advertising services; distribution of samples; wholesale store services featuring nutraceuticals for use as a dietary supplement; wholesale store services featuring medical apparatus; wholesale store services featuring medical apparatus and instruments; advertising agency services for pharmaceuticals; wholesale store services featuring pharmaceuticals; wholesale store services featuring medicines for human purposes; wholesale store services featuring nutraceuticals via the internet; wholesale store services featuring make-up preparations

Advice in the field of construction drafting; engineering surveying; rental of scientific equipment; research relating to mechanical engineering; meteorological observation for others; services for assessing the safety of agricultural chemicals; cosmetology research; industrial design; pharmaceutical drug development services; pharmaceutical product evaluation; pharmaceutical research services; scientific research in the fields of medicine, health and pharmacology; medical research; product safety testing; textile design; research in the field of computer software development; marine, aerial and land surveying; oceanography research; chemical analysis; scientific research in the nature of providing environmental monitoring services

Pharmaceutical agents affecting sensory organs; thyroid and para-thyroid hormone preparations; tonics, namely, medicines for the treatment of autoimmune disease, ocular disease, ear disease, neurodegenerative disease, and cancer; parasiticides; antiemetics; bronchodilating preparations; pharmaceutical preparations for treating diabetes; pharmaceutical agents affecting metabolism; veterinary preparations for the treatment of autoimmune disease, ocular disease, ear disease, neurodegenerative disease, and cancer; prescription synthetic narcotics; anaesthetics; pharmaceutical agents affecting peripheral nervous system; pharmaceutical preparations for immunity improvement; pharmaceutical agents for treating physically caused lesions; pharmaceuticals for the treatment of erectile dysfunction; pharmaceutical preparations for the treatment of urogenital organs; vitamin preparations; pharmaceutical products for the treatment of bone diseases; preparations of trace elements for human and animal use for the treatment of autoimmune disease, ocular disease, ear disease, neurodegenerative disease, and cancer; anti-inflammatory and antipyretic preparations; pharmaceutical agents affecting digestive organs; cardiovascular pharmaceutical preparations; nervines in the nature of herbal supplements; pharmaceutical preparations for the treatment of autoimmune disease, ocular disease, ear disease, neurodegenerative disease, and cancer; chemico-pharmaceutical preparations for the treatment of autoimmune disease, ocular disease, ear disease, neurodegenerative disease, and cancer; medicines for the treatment of gastrointestinal diseases; drugs for medical purposes for the treatment of autoimmune disease, ocular disease, ear disease, neurodegenerative disease, and cancer; medical diagnostic reagents; diuretics; medicines for human purposes for the treatment of autoimmune disease, ocular disease, ear disease, neurodegenerative disease, and cancer; antacids; haematogen; pharmaceutical preparations for treating malignant tumours; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations for diagnosis of autoimmune disease, ocular disease, ear disease, neurodegenerative disease, and cancer; sedatives; analgesics; medical preparations for slimming purposes; dental impression material for dental and dental technical purposes; medicines for dental purposes; dermatological pharmaceutical products; antibiotic preparations; antibiotics; anti-cancer preparations; blood solvents for medical or veterinary purposes; pharmaceutical preparations for the treatment of respiratory organs; preparations for the treatment of burns; chemotherapeutics; medications to treat chemical disorders

Filing History

LIMITATION OF GOODS RECEIVED FROM IB
May 16, 2025 LIMG
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Dec 24, 2024 NRCC
REGISTERED-PRINCIPAL REGISTER
Dec 24, 2024 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Oct 22, 2024 NPUB
PUBLISHED FOR OPPOSITION
Oct 22, 2024 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Oct 2, 2024 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Sep 12, 2024 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Sep 6, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Sep 6, 2024 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Sep 6, 2024 TROA
REFUSAL PROCESSED BY IB
Aug 4, 2024 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Jul 17, 2024 RFCS
REFUSAL PROCESSED BY MPU
Jul 17, 2024 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Jun 26, 2024 RFCR
NON-FINAL ACTION WRITTEN
Jun 25, 2024 CNRT
ASSIGNED TO EXAMINER
Jun 21, 2024 DOCK
APPLICATION FILING RECEIPT MAILED
Feb 27, 2024 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Feb 23, 2024 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Feb 22, 2024 REPR